New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment of moderate-to-severe plaque psoriasis, and its efficacy in patients showing signs of psoriasis-related nail disease and those showed an inadequate early treatment response to the drug.
The first 96 weeks of data derived from 995 participants across two ongoing Phase 3 studies demonstrated that “confirmed the long-term safety of Cimzia in the treatment of psoriasis”, with no new safety concerns flagged, while the overall incidence of adverse events was low.
![[event] Trends & Insights van SXSW 2025: Wat betekent tech voor jouw toekomst?](https://www.pharmamarketeer.nl/wp-content/uploads/2025/04/47922-80x60.jpg)
